Pancreas
General Surgery · Topic 24
Source: NMC CBME Curriculum 2024 · Volume III · General Surgery · competency cluster SU24 · combined PDF page 408
Practice questions
- In developing the 2025 international acute pancreatitis guideline, which framework was used to grade the quality of evidence and strength of recommendations?
- A clinician is checking whether a topic falls within the scope of the 2025 international acute pancreatitis guideline. Which topic is explicitly included?
- A guideline development group frames a clinical question using population, intervention, comparator, and outcome. Which description best matches this approach in the 2025 acute pancreatitis guideline?
- Which set consists entirely of management areas specifically named in the 2025 acute pancreatitis guideline abstract?
- A patient has infected necrotizing acute pancreatitis. Which statement is justified by the 2025 guideline abstract alone?
- Which statement best reflects the breadth of the 2025 international acute pancreatitis guideline?
- In the exocrine pancreas, which function of CFTR is emphasized in the systematic narrative review?
- A pathogenic CFTR variant disrupts protein folding and trafficking, reducing CFTR at the apical membrane of pancreatic duct cells. Which functional consequence is most consistent with the review?
- Which conclusion about CFTR-related exocrine pancreatic dysfunction is appropriately cautious given the review's stated limitations?
- A systematic review and meta-analysis reports fatty-pancreas prevalence of 30.5% among healthy or routine-examination participants and 42.3% across all included populations. Which interpretation is most appropriate?
- In the meta-analysis, fatty pancreas was associated with metabolic syndrome with an odds ratio of 3.90. What is the most defensible interpretation?
- Which associated condition had the largest reported odds ratio with fatty pancreas among the following?
- Which statement about geographic variation in fatty-pancreas prevalence is supported by the meta-analysis?
- In selected adults with type 1 diabetes and end-stage renal disease, what metabolic outcome is consistently associated with successful simultaneous pancreas-kidney transplantation when pancreas graft function is maintained?
- A suitable living kidney donor is available for a patient with type 1 diabetes and end-stage renal disease. Which conclusion best matches the comparative evidence summarized for simultaneous pancreas-kidney transplantation versus living-donor kidney transplantation?
- The systematic review comparing simultaneous pancreas-kidney transplantation with kidney transplantation alone included what type of evidence?
- In the quantitative synthesis of directly comparable adjusted hazard ratios, how did living-donor kidney transplantation compare with simultaneous pancreas-kidney transplantation for patient mortality and kidney graft failure?
- When was the latest revised Japanese pancreatic cancer guideline described in the English synopsis released?
- Which set of domains is included in the 2025 Japanese pancreatic cancer guideline as summarized in the English synopsis?
- A pathology review describes a pancreatic tumor as undifferentiated carcinoma with osteoclast-like giant cells. Approximately what proportion of pancreatic tumors does the review say this variant accounts for?
- According to the review, which histologic grouping has better overall survival in undifferentiated pancreatic carcinoma with osteoclast-like giant cells?
- A clinician is considering neoadjuvant or adjuvant chemotherapy for undifferentiated pancreatic carcinoma with osteoclast-like giant cells. How does the review characterize the evidence for these treatments?
- An engineer increases the cell loading density in an implantable bioartificial pancreas. According to the review, what important trade-off may result?
- A membrane excludes immune cells from an implanted bioartificial pancreas, but the device still shows inflammatory injury. Which explanation is consistent with the review?
- A prototype bioartificial pancreas shows good cell survival in preclinical testing but does not produce clinically meaningful endocrine function. Which interpretation best fits the review?